High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase i Pilot Study for the Eastern Cooperative Oncology Group
Hines, J.D.; Mazza, J.J.; Oken, M.M.; Bennett, J.M.; Adelstein, D.J.; Keller, A.; O'Connell, M.J.
Seminars in Oncology 12(2 Suppl 3: 117-119
1985
ISSN/ISBN: 0093-7754 PMID: 3839318 Document Number: 248829
Document emailed within 1 workday
Related Documents
Arlin, Z.; Case, D.C.; Moore, J.; Wiernik, P.; Feldman, E.; Saletan, S.; Desai, P.; Sia, L.; Cartwright, K. 1990: Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group Leukemia 4(3): 177-183Harakati, M.S. 1999: Cytosine arabinoside, mitoxantrone, and etoposide in the treatment of adult patients with previously untreated acute myeloid leukemia Saudi Medical Journal 20(4): 291-295
Rosenthal, S.; Harris, D.T.; Horton, J.; Glick, J.H. 1980: Phase II study of maytansine in patients with advanced lymphomas: an Eastern Cooperative Oncology Group pilot study Cancer Treatment Reports 64(10-11): 1115-1117
Boros, L.; Tsiatis, A.A.; Neiman, R.S.; Mann, R.B.; Glick, J.H. 1986: Phase Ii Eastern Cooperative Oncology Group Study of spirogermanium in previously treated lymphoma Cancer Treatment Reports 70(7): 917-918
Takemoto, Y.; Sampi, K.; Kuraishi, Y.; Okabe, K.; Tamura, K.; Mizoguchi, H.; Saito, H.; Masaoka, T.; Ogawa, M. 1999: A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. the KRN8602 Leukemia Study Group International Journal of Hematology 70(1): 20-25
Hoelzer, D.; Thiel, E.; Löffler, H.; Büchner, T.; Ganser, A.; Heil, G.; Kurrle, E.; Heimpel, H.; Koch, P.; Lipp, T. 1987: Teniposide (VM-26) and cytosine arabinoside as consolidation therapy in adult high-risk patients with acute lymphoblastic leukemia Seminars in Oncology 14(2 Suppl 1: 92-97
Guilhot, F. 1993: Interferon alfa and low-dose cytosine-arabinoside for the treatment of patients with chronic myelogenous leukemia in chronic phase. French CML Study Group Seminars in Hematology 30(3 Suppl 3: 24-25
Levin, M.; Pandya, K.J.; Khandekar, J.D.; Horton, J.; Glick, J.H.; Bennett, J.M.; Muggia, F.M.; Falkson, G. 1984: Phase Ii study of mitoxantrone in advanced breast cancer: an Eastern Cooperative Oncology Group pilot study Cancer Treatment Reports 68(12): 1511-1512
Trump, D.L.; Elson, P.J.; Borden, E.C.; Harris, J.E.; Tuttle, R.L.; Whisnant, J.K.; Oken, M.M.; Carignan, J.R.; Ruckdeschel, J.C.; Davis, T.E. 1987: High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study Cancer Treatment Reports 71(2): 165-169
Sanz, M.A.; Martínez, J.; Borrego, D.; Martín-Aragonés, G.; Lorenzo, I.; Sanz, G.; Sayas, M.J.; Jarque, I.; Pastor, E.; Rafecas, J. 1987: High-dose cytosine arabinoside and mitoxantrone in high-risk acute nonlymphoblastic leukemia Seminars in Oncology 14(2 Suppl 1): 18-20
Ohshima, A.; Yoshida, K.; Sato, T.; Miyazaki, S.; Yanagisawa, M.; Nakayama, Y.; Takahashi, T.; Mamiya, S.; Fukusima, Y.; Miura, A.B. 1987: Intermediate- and high-dose cytosine arabinoside therapy in acute refractory leukemia Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(1): 192-195
Wysocki, M.; Nowaczyk-Michalak, A.; Pilecki, O.; Trybuś, L.; Balcar-Boroń, A. 1992: Jaundice following high--dose arabinoside cytosine in a child with acute myelogenous leukemia Acta Haematologica Polonica 23(3): 197-199
Yuen, A.R.; Fuks, J.Z.; Ettinger, D.S.; Chang, A.Y.; Ruckdeschel, J.C.; Phan, S.C.; Blum, R.H. 2000: Pilot study with weekly chemotherapy for patients with extensive small cell lung cancer: an Eastern Cooperative Oncology Group Study (PA586) Cancer Journal From Scientific American 6(1): 34-39
Fukuhara, T.; Miyake, T.; Maekawa, I.; Kurosawa, M.; Suzuki, S.; Noto, S.; Mori, A.; Chiba, K.; Toyoshima, T.; Hirano, T.; Morioka, M.; Tsutsumi, Y.; Okabe, M.; Kakinoki, Y. 2000: Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study International Journal of Hematology 71(4): 366-371
Herzig, R.H.; Coccia, P.F.; Lazarus, H.M.; Strandjord, S.E.; Graham-Pole, J.; Cheung, N.K.; Gordon, E.M.; Gross, S.; Spitzer, T.R.; Warkentin, P.I. 1985: Bone marrow transplantation for acute leukemia and lymphoma with high-dose cytosine arabinoside and total body irradiation Seminars in Oncology 12(2 Suppl 3: 184-186
Ghaddar, H.M.; Plunkett, W.; Kantarjian, H.M.; Pierce, S.; Freireich, E.J.; Keating, M.J.; Estey, E.H. 1994: Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside Leukemia 8(8): 1269-1274
Vats, T.S.; Lui, V.; Trueworthy, R.; van Eys, J. 1981: Phase Ii clinical trial of dianhydrogalactitol for remission induction in children with acute leukemia: a Southwest Oncology Group Study Cancer Treatment Reports 65(1-2): 121-122
Rowe, J.M.; Andersen, J.W.; Cassileth, P.A.; Oken, M.M.; Bennett, J.M.; Wiernik, P.H. 1992: Post-remission therapy in adults with acute myelogenous leukemia: the Eastern Cooperative Oncology Group (ECOG) experience Leukemia 6(Suppl 4): 75-77
Paietta, E.; Andersen, J.; Wiernik, P.H. 1996: A new approach to analyzing the utility of immunophenotyping for predicting clinical outcome in acute leukemia. Eastern Cooperative Oncology Group Leukemia 10(1): 1-4
Ettinger, D.S.; Finkelstein, D.M.; Harper, G.R.; Ruckdeschel, J.C.; Chang, A.Y.; Camacho, F.J.; Marsh, J.C.; Silber, R.; Wolter, J.M. 1985: Phase Ii study of mitoxantrone, aclarubicin, and diaziquone in the treatment of non-small cell lung carcinoma: an Eastern Cooperative Oncology Group study Cancer Treatment Reports 69(9): 1033-1034